AarogyaSetu Mitr

Niti Aayog Launches AarogyaSetu Mitr Portal To Help Citizens Combat COVID-19

Niti Aayog has announced the launch of the AarogyaSetu Mitr portal using which you can avail free COVID-19 consultancy, online medicine deliveries including ordering home lab tests. You can avail free consultancy on COVID-19 symptoms directly from the portal. You should note that NITI Aayog has developed the Aarogya Setu app in collaboration with NIC.

The planning body has established a partnership with the Principal Scientific Advisor to the PM to launch AarogyaSetu Mitr. The purpose of the Mitr portal is to bring healthcare services to the doorstep of all Indians at the time of distress with voluntary participation from organizations, industry coalitions, and startups.

The AarogyaSetu Mitr displays three options on the dashboard namely Consult Doctor, Home Lab Test, and ePharmacy. The Consult Doctor section displays the service providers who are offering Telemedicine services such as Tata Bridgital Healthcare, eSanjeevaniOPD, swasth, and Techmahindra’s Connectsense. You can also provide your postal code and the Mitr portal will display it on the top right-hand side.

You can access the services provided by Home Lab providers such as Dr. Lal Pathlabs, SRL Diagnostics, Metropolis, Thyrocare, and others. If you click on the respective button, you will be able to navigate the sites and avail services. Talking about ePharmacy, the AarogyaSetu Mitr helps you to establish connectivity with 1mg, netmeds.com, MedLife, and PharmEasy.

The advantage of AarogyaSetu Mitr portal is that you can know about the authorized service providers approved by the Central Government. You can buy medicines without any worry. With the help of TeleMedicine, you can establish connectivity via chat, call, or video conferencing. The website is a product of Public and Private collaboration under the offices of Niti Aayog and PSA. The service has been integrated inside the Aarogya Setu app and the site is responsive on the mobile.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *